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Abstract Lisdexamfetamine dimesylate (LDX) is a long-
acting d-amphetamine prodrug used to treat attention-def-
icit/hyperactivity disorder (ADHD) in children, adolescents
and adults. LDX is hydrolysed in the blood to yield d-
amphetamine, and the pharmacokinetic profile of d-
amphetamine following oral administration of LDX has a
lower maximum plasma concentration (Cmax), extended
time to Cmax (Tmax) and lower inter- and intra-individual
variability in exposure compared with the pharmacokinetic
profile of an equivalent dose of immediate-release (IR) d-
amphetamine. The therapeutic action of LDX extends to at
least 13 h post-dose in children and 14 h post-dose in
adults, longer than that reported for any other long-acting
formulation. Drug-liking scores for LDX are lower than for
an equivalent dose of IR d-amphetamine, which may result
from the reduced euphorigenic potential associated with its
pharmacokinetic profile. These pharmacokinetic and
pharmacodynamic characteristics of LDX may be
beneficial in the management of symptoms in children,
adolescents and adults with ADHD.
Key Points
Lisdexamfetamine dimesylate (LDX) is the first, and
so far the only, long-acting stimulant in which the
active drug is released biochemically in the blood
rather than mechanically in the gastrointestinal tract.
The duration of therapeutic action of LDX is longer
than that reported for any other long-acting stimulant
medication, and extends to at least 13 h post-dose in
children and 14 h post-dose in adults with ADHD.
The pharmacokinetic and pharmacodynamic
characteristics of LDX may be beneficial in the
management of symptoms in children, adolescents
and adults with ADHD.
1 Introduction
The stimulants amphetamine and methylphenidate (MPH)
are long-established and effective treatments for attention-
deficit/hyperactivity disorder (ADHD) in children, adoles-
cents and adults [1]. The therapeutic effects of immediate-
release (IR) formulations, however, wear off within 4–6 h,
necessitating repeated dosing to achieve symptom control
throughout the day [2–5]. To extend the efficacy of stim-
ulants throughout the day and into the evening following a
single morning dose, long-acting stimulants have been
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developed [6]. These rely on the gradual and phased
release of amphetamine or MPH in the gastrointestinal (GI)
tract and, for certain formulations, the duration of action
has been reported to extend for up to 12 h post-dose [7].
Lisdexamfetamine dimesylate (LDX) is the first stimu-
lant prodrug [8], and is approved for the treatment of
children, adolescents and adults with ADHD in the USA,
Canada, Brazil and Australia. In Europe, it is the only
available long-acting amphetamine and is approved in
selected countries for the treatment of children and ado-
lescents with a clinically inadequate response to MPH. In
Denmark, Sweden and the UK, it is also approved for the
treatment of adults with ADHD. LDX has also received
approval in the USA for the treatment of moderate to
severe binge eating disorder in adults [9].
Unlike other long-acting stimulants, the active drug is
not released in the GI tract following oral administration.
Instead, the pharmacologically inactive parent molecule,
consisting of d-amphetamine covalently linked to L-lysine
(Fig. 1), is rapidly and actively taken up from the small
intestine by carrier-mediated active transport [10], proba-
bly via the oligopeptide transporter peptide transporter 1
(PEPT1) [11]. Once in the blood, LDX is hydrolysed in
erythrocyte cytosol by an unknown aminopeptidase,
yielding pharmacologically active d-amphetamine (Fig. 2)
[11, 12]. The d-amphetamine generated from LDX crosses
the blood-brain barrier to access binding sites in the central
nervous system [13] and to exert therapeutic effects by
increasing noradrenergic and dopaminergic neurotrans-
mission. Here, we discuss the relevance of this distinctive
mode of action to clinicians and patients by reviewing the
pharmacokinetics and pharmacodynamics of d-am-
phetamine delivered by hydrolysis of LDX. Relevant
journal articles and clinical studies were identified by
searching PubMed and ClinicalTrials.gov for ‘lisdexam-
fetamine’ or ‘SPD489’.
2 Pharmacokinetics of d-Amphetamine Delivered
by Hydrolysis of Lisdexamfetamine Dimesylate
(LDX)
2.1 Plasma Concentration–Time Profiles for d-
Amphetamine Following Oral LDX
Administration
The pharmacokinetic parameters that describe blood
plasma concentration-time profiles and thereby quantify an
individual’s exposure to LDX or d-amphetamine are
defined in Table 1.
Figure 3, panels a and b, show the observed blood
plasma concentration-time profiles for intact LDX and d-
amphetamine following oral administration of LDX in
children with ADHD (N = 17) [14] and healthy adults
(N = 11) [15], respectively. Tables 2 and 3 summarise
published pharmacokinetic parameters for d-amphetamine

















Fig. 1 Chemical structure of LDX and immediate metabolites. In the
inactive prodrug LDX, a peptide bond links the amino group of d-
amphetamine to the carboxyl group of L-lysine. Enzymatic hydrolysis
of this bond releases active d-amphetamine, and also yields L-lysine
















by unknown erythrocyte peptidase
Active transport
probably via PEPT1
Fig. 2 Systemic delivery of d-
amphetamine by hydrolysis of
LDX in the blood. LDX
lisdexamfetamine dimesylate,
PEPT1 peptide transporter 1
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the therapeutic range (30, 50 or 70 mg/day) to children
with ADHD, healthy adults and healthy older adults. The
mean time to maximum plasma concentration (Tmax) is
longer for d-amphetamine (3.0–4.7 h) than for LDX
(1.0–2.1 h), because of the rate-limited hydrolysis of the
parent drug. After peaking, plasma LDX concentrations
declined rapidly (mean elimination half-life [t],
0.4–0.9 h), whereas d-amphetamine was cleared more
slowly (mean t, 8.6–15.0 h). Exposure to d-amphetamine
(maximum plasma concentration [Cmax] and area under the
plasma concentration-time curve from zero to infinity
[AUC0–?]) were linearly proportional to LDX dose in
children with ADHD within the therapeutic dose range
(Table 2; Fig. 3a) [14] and in healthy adults at therapeutic
and supratherapeutic doses (N = 20) [16].
2.2 Comparison of d-Amphetamine
Pharmacokinetics Following Oral LDX
or Immediate-Release d-Amphetamine
Data directly comparing d-amphetamine pharmacokinetic
profiles following oral administration of LDX or an IR d-
amphetamine formulation are limited to a single-blind
study involving a supratherapeutic dose of LDX in three
cohorts of adults with histories of stimulant abuse
(N = 12). The mean plasma d-amphetamine Tmax in each
cohort occurred 1 h later following administration of LDX
100 mg (range 3.78–4.25 h) than for an equivalent dose of
d-amphetamine sulfate (40 mg; 1.88–2.74 h) [17], sug-
gesting that the systemic delivery of d-amphetamine from
LDX is dependent upon the rate-limiting conversion of the
parent molecule.
2.3 Consistency of Exposure to d-Amphetamine
Following LDX Administration
Reliable symptom control by LDX is dependent on pre-
dictable and consistent exposure to d-amphetamine.
Table 2 shows that d-amphetamine exposure was generally
consistent across studies for a given LDX dose and age
group, but that some age-related variability in d-am-
phetamine exposure was apparent. In children with ADHD,
both d-amphetamine Cmax and AUC0–? for given doses of
LDX were higher than in healthy adults, presumably
reflecting differences in body size. Also, in healthy adults
aged 55–74 years and 75 years and older, d-amphetamine
exposure was higher and t longer than in younger adults.
This observation may be explained by a decrease in d-
amphetamine clearance with age due to reduced renal
function [18].
Within-study variability in d-amphetamine exposure
may be expressed as the percentage coefficient of variation
(% CV = [parameter standard deviation/parameter
mean] 9 100) for Cmax, AUC0–t and AUC0–?. Percent
CVs below 30 are considered to represent low variability
[19]. Table 2 shows that % CVs for d-amphetamine
exposure following doses of LDX were generally low (in
the range 12.1–35.7), irrespective of age. In a single-dose
study in healthy adults, both intra- and inter-individual %
CVs for d-amphetamine exposure (log Cmax and log
AUC0–?) were low following administration of a wide
range of doses of LDX (50–250 mg); all but the 50 mg
dose were supratherapeutic [16]. These data indicate that
d–amphetamine is delivered consistently and predictably
following LDX administration. In contrast, within-study
inter-individual % CVs for intact LDX exposure were
nearly always higher than the equivalent values for d-am-
phetamine (Table 3).
2.4 Gastrointestinal Factors Influencing d-
Amphetamine Pharmacokinetics Following
LDX Administration
Factors that influence a drug’s rate of transit through, and
uptake from, the GI tract include the presence of food and
pH [20–22]. In a single-dose crossover study, Krishnan and
Zhang [23] reported that d-amphetamine Tmax was delayed
by approximately 1 h in healthy adults (N = 18) admin-
istered LDX 70 mg following a high-fat meal compared
with those who fasted; there were no significant differences
in Cmax, AUC0–? or t (Table 2; high-fat meal defined in
legend). In contrast, while Tmax for intact LDX also
exhibited a significant delay of approximately 1 h, Cmax
was significantly lower and t significantly longer in the
fed than in the fasted state, although AUC0–? was unaf-
fected (N = 8) (Table 3) [24]. Following orally adminis-
tered extended-release mixed amphetamine salts (MAS
XR), however, the mean Tmax of plasma d-amphetamine
was reported as approximately 2.5 h longer in fed than in
fasted individuals, with Cmax and AUC0–? modestly lower
[21, 22]. These results suggest that LDX hydrolysis, rather
than GI transit and uptake, is the dominant factor in
Table 1 Interpreting
pharmacokinetic parameters
Cmax Maximum plasma concentration: provides a measure of peak drug exposure
AUC0–t Area under the plasma concentration–time curve from time zero to another specified time (t):
provides a measure of overall drug exposure
Tmax Time to Cmax: relevant to speed of onset
t Elimination half-life: relevant to duration of efficacy
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SKAMP and PERMP [24] Children
Adults
SKAMP and PERMP [57]*
SKAMP [59]
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d-Amphetamine from LDX 30 mg
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Intact LDX from LDX 70 mg
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Fig. 3 Pharmacokinetic profiles of plasma LDX and d-amphetamine
a after a single oral dose of LDX in children with ADHD (N = 17)
[14] (Reproduced from ‘Pharmacokinetics of lisdexamfetamine
dimesylate and its active metabolite, d-amphetamine, with increasing
oral doses of lisdexamfetamine dimesylate in children with attention-
deficit/hyperactivity disorder: a single-dose, randomized, open-label,
crossover study’, Boellner SW et al. Clinical Therapeutics
2010;32:252–64. 2010 Excerpta Medica Inc. Reproduced with
permission from Elsevier), b on day 7 of daily oral LDX dosing in
healthy adults (N = 11) [15] (Krishnan SM and Stark JG, Current
Medical Research and Opinion 2008;24:33–40, copyright 2008
Informa Healthcare. Adapted with permission of Informa Healthcare),
and c timings of symptomatological (SKAMP, CPRS-R) or functional
(PERMP) assessments in studies of the efficacy of LDX throughout
the day [8, 24, 57, 59, 60, 62]. Asterisk Effect sizes for LDX versus
placebo in these studies are presented in Fig. 4. Biederman et al. [24]
used a post-dose time point as baseline. ADHD attention-deficit/
hyperactivity disorder, CPRS-R Connors’ Parent Rating Scale-Re-
vised, LDX lisdexamfetamine dimesylate, PERMP Permanent Product
Measure of Performance, SKAMP Swanson, Kotkin, Agler, M-Flynn,
and Pelham
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determining the d-amphetamine exposure profile following
oral administration of LDX.
GI disorders, including ulcers and dyspepsia, are com-
monly treated using proton pump inhibitors, such as
omeprazole, to suppress acid secretion by the stomach
mucosa and thereby increase the pH. The inhibition of
gastric acid secretion may, however, interfere with the
absorption of drugs for which pH is an important deter-
minant of bioavailability [25], such as MAS XR which uses
pH-sensitive beaded technology to achieve phased release.
Haffey et al. [26] reported that the median Tmax for total
amphetamine was approximately 2 h shorter in healthy
adults when MAS XR was co-administered with omepra-
zole (Tmax, 2.75 h) than when administered alone (Tmax, 5
h) (N = 24). In the same study, d-amphetamine pharma-
cokinetic parameters remained largely unaltered when
LDX was co-administered with oral omeprazole (Table 2).
Thus, these results indicate that, unlike MAS XR, LDX
provided an amphetamine exposure profile that was unaf-
fected by administration of a proton pump inhibitor.
LDX is soluble in water [9] and can, therefore, be
administered as a solution or mixed into food to individuals
who experience difficulty in swallowing capsules, or in
circumstances when the monitoring of drug consumption is
a requirement. This differs from other long-acting stimu-
lant formulations which rely on mechanical phased release
of the active drug from a capsule. In another study
(NCT01890785), similar values of d-amphetamine Cmax
and AUC0–96h were seen when oral LDX 70 mg was
administered to healthy adults as capsules, or capsule
contents were dissolved in orange juice or mixed into
vanilla yogurt [27]; in addition administration with yogurt
delayed Tmax by only 0.4 h compared with the fasted state
[9].
To summarise, the above LDX single-dose studies
suggest that the hydrolysis of LDX to d-amphetamine in
the blood is the rate-limiting step, rather than the uptake of
the parent drug from the GI tract. This leads to consistent
intra- and inter-individual d-amphetamine exposure
profiles.
2.5 Multiple Once-Daily Dosing of LDX
In a study of multiple once-daily dosing of LDX 70 mg in
healthy adults, Krishnan and Stark [15] observed that
steady-state plasma d-amphetamine concentrations were
achieved by day five [15, 28]. At steady state, pre-dose
plasma d-amphetamine concentrations were approximately
20 ng/mL, and Cmax following each daily dose was
approximately 90 ng/mL (Fig. 3b), moderately higher than
following a single 70 mg dose in adults (Table 2) [15]. The
values for d-amphetamine Tmax, t and AUC0–? were
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whether steady state had previously been reached
(Table 2). These results suggest that d-amphetamine
exposure reaches therapeutic levels after a single dose of
LDX and that systemic concentrations of d-amphetamine
do not markedly increase with multiple once-daily dosing.
2.6 Effect of Route of Administration of LDX
or Immediate-Release d-Amphetamine
on Plasma d-Amphetamine Pharmacokinetics
The abuse of stimulants often involves intranasal or intra-
venous administration to shorten stimulant blood plasma
Tmax and increase Cmax, thereby enhancing the euphori-
genic potential [29–31]. The pharmacokinetics of intra-
venous LDX compared with intravenous d-amphetamine
were evaluated in a single-dose, crossover study in adults
with a history of stimulant abuse (N = 9). Mean (SD) d-
amphetamine Tmax was shorter and Cmax higher following
intravenous IR d-amphetamine (20 mg; Tmax, 0.8 h [1.3];
Cmax, 105 ng/mL [91.4]) than after an equivalent dose of
intravenous LDX (50 mg; Tmax, 2.5 h [1.5]; Cmax, 38.9 ng/
mL [8.1]) [32]. This more gradual approach to a lower peak
plasma d-amphetamine concentration for LDX compared
with IR d-amphetamine presumably resulted from rate-
limited hydrolysis of the prodrug in the blood. The impact
of the route of administration was further explored in a
single-dose, crossover study in healthy adults, which found
no difference in d-amphetamine pharmacokinetics follow-
ing oral and intranasal administration of LDX 50 mg
(N = 18) (Table 4) [33].
2.7 Impact of Compromised Erythrocytes
and Haematocrit Level on the Generation of d-
Amphetamine from LDX
The effects on LDX metabolism of moderately compro-
mised erythrocytes and low haematocrit have been inves-
tigated in vitro. The rate of LDX hydrolysis was similar in
blood from donors with or without sickle cell disease [34].
Furthermore, the rate of LDX hydrolysis was haematocrit-
dependent, but substantial d-amphetamine production was
still observed at 10 % of normal haematocrit [11]. These
results suggest that LDX biotransformation is unaffected
by clinically relevant variations in erythrocyte viability and
levels [11, 34].
2.8 Potential for Drug–Drug Interactions
In vitro evidence indicates that LDX itself does not interact
with the major cytochrome P450 (CYP) isoforms com-
monly inhibited or induced by therapeutic drugs (CYP1A2,
2A6, 2B6, 2C9, 2C19, 2D6, 3A4/5 [35] and 2C8 [36]), and





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































LDX: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy 349
P-glycoprotein [36]. Other in vitro studies suggest that
amphetamine weakly inhibits CYP2D6 [37] and 2A6 [38],
and that its metabolites weakly inhibit CYP2D6, 1A2 and
3A4 [39].
In an in vivo study designed to investigate whether LDX
affects the activity of CYP isoforms, the following drugs
were administered to healthy individuals in the form of a
Cooperstown cocktail with or without LDX: caffeine (a
CYP1A2 substrate), dextromethorphan (a CYP2D6 sub-
strate), midazolam (a CYP3A substrate) and omezaprole
(the proton pump inhibitor described in the ‘gastrointesti-
nal factors’ section and a CYP2C19 substrate). The phar-
macokinetic profiles of d-amphetamine and LDX were
similar to those observed in other studies (Tables 2, 3).
Furthermore, LDX had no effect on the activity of
CYP1A2, 2D6 or 3A as determined by the Cmax and AUC0–
? of their respective substrates. For omeprazole a small
decrease in Cmax was observed, possibly indicating that
LDX may have an effect either on CYP2C19 activity or on
omeprazole absorption [40].
In vivo, co-administration of LDX with extended-re-
lease guanfacine, an a2-adrenoreceptor agonist that is
approved in the USA [41] and Canada [42] for treatment of
ADHD in combination with psychostimulants (and is a
CYP3A4 substrate), led to no clinically meaningful dif-
ference in d-amphetamine or guanfacine pharmacokinetic
profiles [43]. When LDX was co-administered with ven-
lafaxine, a serotonin-noradrenaline reuptake inhibitor that
is predominantly metabolised by CYP2D6 [44], there was
no change in d-amphetamine pharmacokinetics. Although a
small decrease in exposure to O-desmethylvenlafaxine (the
active metabolite of venlafaxine) was observed, total
exposure to venlafaxine plus O-desmethylvenlafaxine was
unaffected [28].
3 Pharmacodynamics of d-Amphetamine
Delivered by Hydrolysis of LDX
3.1 Efficacy Throughout the Day Following
an Early-Morning Dose of LDX
The pharmacokinetics of d-amphetamine delivered by
hydrolysis of LDX are reflected in the duration of the
therapeutic action following an early-morning dose of
LDX. Although the shorter d-amphetamine Tmax for IR
amphetamine compared with LDX leads to more rapid
initial symptom control, the therapeutic effects of IR
amphetamine and IR MAS do not extend beyond 4–6 h in
children with ADHD [2–5, 45] or hyperkinetic disorder
[46, 47]. This necessitates multiple daily doses of IR
amphetamine or IR MAS to extend symptom control into
the afternoon and evening [2].
Extended-release formulations have been developed to
provide prolonged drug delivery [3, 48–55]. To date, LDX
is the only prodrug ADHD medication, the only long-act-
ing stimulant that does not rely on mechanical phased
release, and the only stimulant for which efficacy in
treating the symptoms of ADHD has been demonstrated
beyond 12 h post-dose [56]. The duration of action of LDX
following an early-morning dose has been evaluated in a
series of model environment studies and phase III clinical
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Fig. 4 Analyses of the effect sizes of LDX versus placebo in
a children with ADHD in an analogue classroom study (post-hoc)
[58] and b adults with ADHD in a model workplace study [61] (Effect
size of lisdexamfetamine dimesylate in adults with attention-deficit/
hyperactivity disorder, Wigal T et al. Postgraduate Medicine 2011
123:169–76, Informa Healthcare. Reprinted by permission of the
publisher Informa healthcare http://informahealthcare.com/) LDX
demonstrated significant improvement versus placebo, by effect size,
at all post-dose time points in both studies. For PERMP, positive
effect sizes indicate superiority over placebo; for SKAMP, negative
effect sizes indicate superiority over placebo. ADHD attention-deficit/
hyperactivity disorder, LS least-squares, SE standard error, SEM
standard error of the mean, SKAMP Swanson, Kotkin, Agler,
M-Flynn, and Pelham, PERMP Permanent Product Measure of
Performance
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ADHD. Figure 3 illustrates how the timings of efficacy
assessments in these studies (Fig. 3c) relate to the phar-
macokinetic profiles of intact LDX and d-amphetamine
following a single dose of LDX 30, 50 and 70 mg (Fig. 3a)
or after the last of seven daily doses of LDX 70 mg
(Fig. 3b).
Two randomised, double-blind, placebo-controlled,
crossover analogue classroom studies in children (aged
6–12 years) with ADHD have studied changes in scores on
the Swanson, Kotkin, Agler, M-Flynn, and Pelham
(SKAMP) and Permanent Product Measure of Performance
(PERMP) scales. In the first study (N = 117), dose-opti-
mised LDX led to marked, sustained and statistically sig-
nificant (p\ .005) improvements in the SKAMP
Deportment and Attention subscale scores and PERMP
scale scores from 1.5 h to at least 13 h post-dose (last
assessment) compared with placebo [57]. Post hoc analyses
showed that effect sizes in favour of LDX over placebo
remained large from 2.5 h until at least 13 h post-dose
(range 0.84–1.11) for SKAMP total and PERMP Attemp-
ted and Correct scores (Fig. 4a) [58]. In the second class-
room study (N = 52), significant (p\ .001) improvements
compared with placebo in SKAMP Deportment and
Attention subscale scores and PERMP Attempted and
Correct scores were maintained for 12 h (last assessment)
after an optimised dose of LDX [24]. Additionally, a
summer camp study in children with ADHD (N = 25)
investigated the relative effectiveness of dose-optimised
LDX, intensive behavioural intervention and a combination
of both treatments. Compared with intensive behavioural
intervention alone, the overall magnitude of changes in
SKAMP scores were large for both LDX alone (effect size,
1.16) and combined treatment (effect size, 1.14), and the
benefits were maintained until the last assessment (12.5 h
post-dose) [59].
The duration of action of LDX in adults with ADHD
was evaluated in a randomised, double-blind, placebo-
controlled, crossover study in a simulated workplace
environment (N = 127). Compared with placebo, both
absolute (p B .0017) and change from baseline (p\ .001)
PERMP total scores were significantly improved at all
post-dose assessments from 2 to 14 h [60]. Medium-to-
large least-squares mean model-based effect sizes for
PERMP Attention and Correct scores were maintained for
up to 14 h after LDX administration (Fig. 4b) [61].
Two randomised, double-blind, phase III clinical trials
have used the Conners’ Parent Rating Scale-Revised
(CPRS-R) to assess the duration of therapeutic response in
children and adolescents (6–17 years) with ADHD.
Although the range of post-dose assessment time points
was not as extensive as in the model environment studies
and the outcomes relied on parent/caregiver reports rather
than direct observations, these phase III clinical trials
enrolled large patient numbers and provide robust data. At
endpoint in a 7-week, dose-optimised, European trial in
children and adolescents with ADHD (N = 336), differ-
ences between LDX and placebo in least-squares mean
change from baseline in CPRS-R total score were statisti-
cally significant (p\ .001) at 10 am, 2 pm and 6 pm fol-
lowing an early-morning dose (approximately 7 am), with
effect sizes maintained in the range 1.30–1.42 [62]. Simi-
larly, in a 4-week, fixed-dose, US trial in children
(6–12 years) with ADHD (N = 290), the reductions in
CPRS-R scores were significantly greater for LDX 30, 50
and 70 mg than for placebo at all three assessment times
(p\ .001) [8].
3.2 Safety
The safety profile of LDX, including treatment-emergent
adverse events (TEAEs), vital sign changes and laboratory
signs is consistent with the known safety profile of stim-
ulants used in the treatment of ADHD, and has been
recently reviewed [63]. Here we further review in greater
detail two safety concerns associated with stimulants that
are particularly pertinent to the pharmacokinetic and
pharmacodynamic characteristics of LDX: effects on sleep
and the potential for abuse, misuse and diversion as
determined by drug-liking scores.
3.2.1 Effect of LDX on Sleep
Sleep-related TEAEs are a consistent finding in clinical
trials of stimulant medications in individuals of all ages
with ADHD [64, 65]. With the duration of efficacy of LDX
extending at least into the evening, the effect on sleep-
related TEAEs is of clinical interest, although the propor-
tion of patients who experience TEAEs during a clinical
study does not provide information about the time of onset
or the duration of the TEAE. The incidence of insomnia as
a TEAE in short-term, randomised, double-blind, parallel-
group, phase III clinical trials of LDX ranges from 11.2 to
18.8 % in children and/or adolescents [8, 66–68], and from
12.7 to 19.3 % in adults [69, 70], compared with rates of
4.8 % or below in individuals receiving placebo. In longer-
term safety and efficacy extension studies of at least
6 months’ duration, the incidence of insomnia as a TEAE
in individuals with ADHD who were receiving LDX was
similar to that in the short-term trials: 17.3 % in children
[71], 12.1 % in adolescents [72], 14.1 % in children and
adolescents [73], and 19.5 % in adults [74].
The relationships between stimulant treatment, the
incidence of sleep-related TEAEs, and sleep disturbance
are not, however, straightforward because ADHD itself is
associated with disturbance of sleep [75–77], which may be
exacerbated in the evening if the efficacy of medication
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wanes [64, 65, 78]. In a short-term, phase III trial in adults
with ADHD, despite sleep-related TEAEs being reported
by a higher proportion of individuals receiving LDX (109/
358, 30.4 %) than by those taking placebo (9/62, 14.5 %),
there was no difference at endpoint in the mean global
Pittsburgh Sleep Quality Instrument (PSQI) score, a sub-
jective assessment of sleep quality, among those reporting
sleep-related TEAEs. Indeed, significant improvements
were observed in the LDX group compared with the pla-
cebo group in one of the PSQI components (daytime
functioning, p = .0001), leading the authors to caution
against relying on self-reported TEAEs alone as an indi-
cation of the effect of stimulant medications on sleep [79].
In a post hoc analysis of this study, a greater proportion of
individuals in the LDX group (20.9 %) than in the placebo
group (8.2 %) demonstrated better sleep at endpoint than at
baseline, and the relationship between treatment group and
endpoint PSQI score was statistically significant (p = .03)
[80]. Furthermore, the relationship between clinically
meaningful improvements in the symptoms of ADHD
(defined as Clinical Global Impressions-Improvement
[CGI-I] scores of 1 or 2) and improved sleep (i.e. decreased
PSQI scores) was statistically significant (p = .0008) [80].
In a laboratory sleep study [81], children (6–12 years) with
ADHD (N = 24) were randomised (2:1) to receive an
optimal dose of LDX (30, 50 or 70 mg based on thera-
peutic response during a 3-week open-label dose-optimi-
sation period) or placebo. This study found no difference
between individuals treated with LDX and those who
received placebo in the polysomnographic assessments of
latency to persistent sleep, wake time after sleep onset or
total sleep time, but the number of awakenings after sleep
was significantly decreased in those receiving LDX com-
pared with participants who received placebo (p\ .0001)
[81].
3.2.2 Drug-Liking Scores for LDX Compared
with Immediate-Release Amphetamine
Drug-liking scores for LDX and IR d-amphetamine have
been compared following oral and intravenous adminis-
tration. On the primary measure of abuse liability in a
double-blind, randomised, placebo-controlled, crossover
study in individuals with a history of stimulant abuse
(N = 36), the maximum change of the Drug Rating
Questionnaire-Subject (DRQS) Liking scale score was not
significantly different from placebo for oral LDX 50 and
100 mg, but was significant (p\ .001) at the suprathera-
peutic dose of 150 mg. In addition, participants signifi-
cantly favoured oral IR d-amphetamine 40 mg over an
equivalent oral dose of LDX (100 mg, p\ .05) but not
LDX 150 mg. Furthermore, mean peak DRQS Liking scale
scores for LDX were observed approximately 3 h (LDX 50
and 100 mg) or 4 h (LDX 150 mg) post-dose compared
with 1.5–2 h post-dose for d-amphetamine 40 mg [82].
In a second double-blind, randomised, placebo-con-
trolled, crossover study conducted in individuals with a
history of intravenous drug abuse (N = 9), maximum mean
change in DRQS Liking scale scores for intravenous d-
amphetamine 20 mg (5.6 [standard error, 1.3]) was sig-
nificantly (p = .01) different from placebo (0.0 [1.3]),
whereas scores for an equivalent intravenous dose of LDX
50 mg (2.1 [1.3]) did not differ from those for placebo
(p = .290) [32].
A post hoc analysis of these two drug-liking studies
revealed that the subjective effects of LDX were not sta-
tistically significantly different when the drug was admin-
istered orally versus intravenously, in keeping with the
broadly similar d-amphetamine pharmacokinetic profiles
generated by LDX following oral and intravenous admin-
istration. In contrast, the subjective effects of IR amphe-
tamine are both larger and more rapid in onset when
administered intravenously than when administered orally
[30]. These results, presumably reflecting the delayed Tmax
and lower Cmax of the d-amphetamine pharmacokinetic
profile, suggest that LDX may have a lower abuse potential
than IR d-amphetamine.
Real-world data from a retrospective, observational case
series of single-substance exposures to LDX (7,113 cases),
dextroamphetamine/amphetamine IR (10,195 cases) or
dextroamphetamine/amphetamine XR (6245 cases) is
suggestive of a lower potential for abuse/misuse of LDX
[83]. The study reports the odds of abuse/misuse was 2.3
(95 % confidence interval [CI] 2.0–2.4) times higher for
dextroamphetamine/amphetamine IR than that for LDX
and dextroamphetamine/amphetamine XR combined. The
odds of abuse/misuse of dextroamphetamine/amphetamine
XR was 1.9 (95 % CI 1.7–2.2) times higher than
lisdexamfetamine.
3.3 Why Might the Daily Duration of Efficacy
of LDX Exceed that of Immediate-Release
Amphetamine?
Regardless of whether d-amphetamine is delivered via
oral LDX or an IR formulation, the plasma d-am-
phetamine t is approximately 10 h, and the AUC0–? is
roughly similar for equivalent doses [2, 21, 26, 39, 84].
This raises the question of why the daily therapeutic
duration of action of LDX is at least threefold that of IR
amphetamine. The explanation may lie in the fact that the
rate of increase in plasma d-amphetamine concentration is
less steep (i.e. Tmax is longer) and Cmax is lower following
oral administration of LDX compared with IR ampheta-
mine [85], which suggests that acute tolerance (tachy-
phylaxis) could be a factor.
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Acute tolerance may be defined as a reduction in
response to a drug over the course of a single exposure. In
other words, for a given drug plasma concentration, ther-
apeutic effects (and side effects) are greater when the drug
plasma concentration is rising than when it subsequently
declines. In terms of ADHD medication, acute tolerance to
MPH has been observed, and understanding this phe-
nomenon has led to improvements in long-acting formu-
lations to treat ADHD [48–51, 54, 55]. Specifically,
Swanson et al. [48] reported that a second bolus of MPH
was less effective when given in the declining phase of
plasma MPH concentration than in the ascending phase
following an initial dose. This finding led to the discovery
that a long-acting formulation delivering an ascending
(rather than flat) profile of plasma MPH concentration was
as effective in providing relief of ADHD symptoms
through the day as three equally spaced doses of IR MPH
per day [53].
Acute tolerance to the subjective effects of oral d-am-
phetamine 20 mg has been observed in healthy adults [29],
and the potential for LDX and IR d-amphetamine to cause
acute tolerance has been investigated in rats by measuring
plasma d-amphetamine concentrations, striatal extracellu-
lar concentrations of the neurochemical mediator dopamine
and locomotor activity (as a behavioural outcome). The
overall d-amphetamine exposure was similar for equivalent
doses of both drugs, but delivery of the active drug via rate-
limited hydrolysis resulted in a lower d-amphetamine Cmax
and delayed Tmax for LDX than for IR d-amphetamine.
Compared with IR d-amphetamine, the pharmacokinetic
profile of plasma d-amphetamine produced by LDX led to
behavioural activation that was less pronounced as extra-
cellular striatal dopamine concentrations increased, but was
maintained for longer as extracellular striatal dopamine
concentrations decreased [86]. One potential explanation
for these observations may be lower acute tolerance to d-
amphetamine when generated from the prodrug than for IR
d-amphetamine which, in turn, may be responsible for the
extended daily duration of therapeutic action and reduced
drug-liking effects of LDX compared with IR ampheta-
mine formulations.
4 Conclusions
The hydrolysis of LDX produces a plasma d-amphetamine
pharmacokinetic profile with lower Cmax, extended Tmax
and lower inter- and intra-individual variability than that
produced by an equivalent dose of IR d-amphetamine. The
therapeutic duration of action of LDX is considerably
longer than that of an equivalent dose of IR d-am-
phetamine, possibly because reduced acute tolerance
means that behavioural effects of LDX are maintained into
the declining phase of the plasma d-amphetamine con-
centration-time curve. The safety profile of LDX is typical
of the stimulant class of ADHD medications. The reduced
drug-liking profile of LDX compared with IR d-am-
phetamine formulations at equivalent doses may reflect the
lower plasma d-amphetamine Cmax and delayed Tmax of the
prodrug that therefore reduce the euphorigenic potential.
These pharmacokinetic and pharmacodynamic character-
istics of LDX may be beneficial in the management of
symptoms in patients with ADHD.
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